2,646 Shares in Natera, Inc. $NTRA Purchased by MGO One Seven LLC

MGO One Seven LLC acquired a new position in shares of Natera, Inc. (NASDAQ:NTRA) in the fourth quarter, according to its most recent Form 13F filing with the SEC. The firm acquired 2,646 shares of the medical research company’s stock, valued at approximately $606,000.

Other hedge funds and other institutional investors have also recently modified their holdings of the company. JPMorgan Chase & Co. boosted its holdings in Natera by 9.4% during the 3rd quarter. JPMorgan Chase & Co. now owns 11,628,914 shares of the medical research company’s stock valued at $1,871,914,000 after acquiring an additional 1,003,129 shares during the period. State Street Corp boosted its holdings in Natera by 2.2% during the 3rd quarter. State Street Corp now owns 3,389,599 shares of the medical research company’s stock valued at $545,624,000 after acquiring an additional 72,087 shares during the period. Franklin Resources Inc. boosted its holdings in Natera by 37.5% during the 3rd quarter. Franklin Resources Inc. now owns 2,665,013 shares of the medical research company’s stock valued at $428,987,000 after acquiring an additional 727,366 shares during the period. Fred Alger Management LLC boosted its holdings in Natera by 1.7% during the 3rd quarter. Fred Alger Management LLC now owns 2,451,779 shares of the medical research company’s stock valued at $394,663,000 after acquiring an additional 41,303 shares during the period. Finally, AQR Capital Management LLC boosted its holdings in Natera by 39.0% during the 3rd quarter. AQR Capital Management LLC now owns 2,400,065 shares of the medical research company’s stock valued at $386,338,000 after acquiring an additional 673,315 shares during the period. 99.90% of the stock is owned by institutional investors and hedge funds.

Wall Street Analysts Forecast Growth

NTRA has been the subject of a number of research analyst reports. Wall Street Zen cut Natera from a “buy” rating to a “hold” rating in a report on Saturday, May 9th. Piper Sandler restated an “overweight” rating and set a $249.00 target price on shares of Natera in a report on Tuesday. Wells Fargo & Company raised their target price on Natera from $215.00 to $220.00 and gave the company an “equal weight” rating in a report on Friday, May 8th. Evercore reiterated an “outperform” rating and issued a $270.00 price objective on shares of Natera in a research note on Friday, May 8th. Finally, BTIG Research decreased their price objective on Natera from $260.00 to $250.00 and set a “buy” rating for the company in a research note on Monday. One research analyst has rated the stock with a Strong Buy rating, fourteen have assigned a Buy rating, three have given a Hold rating and one has issued a Sell rating to the stock. According to data from MarketBeat.com, Natera currently has an average rating of “Moderate Buy” and a consensus price target of $256.60.

Insiders Place Their Bets

In other Natera news, CEO Steven Leonard Chapman sold 902 shares of Natera stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $206.16, for a total transaction of $185,956.32. Following the transaction, the chief executive officer owned 149,867 shares of the company’s stock, valued at $30,896,580.72. The trade was a 0.60% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this hyperlink. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Also, insider John Fesko sold 291 shares of Natera stock in a transaction that occurred on Friday, May 1st. The stock was sold at an average price of $206.16, for a total value of $59,992.56. Following the transaction, the insider directly owned 187,220 shares in the company, valued at approximately $38,597,275.20. This trade represents a 0.16% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. The sale was made to cover tax withholding obligations related to the vesting of equity awards. Insiders have sold 38,266 shares of company stock worth $7,747,808 in the last three months. 5.63% of the stock is owned by company insiders.

Natera Stock Down 4.4%

NTRA stock opened at $195.32 on Thursday. The business has a 50 day moving average price of $201.36 and a 200 day moving average price of $215.26. The stock has a market cap of $27.97 billion, a price-to-earnings ratio of -119.83 and a beta of 1.57. Natera, Inc. has a fifty-two week low of $131.81 and a fifty-two week high of $256.36.

Natera (NASDAQ:NTRA) last posted its earnings results on Thursday, February 26th. The medical research company reported $0.35 earnings per share for the quarter, topping the consensus estimate of ($0.46) by $0.81. The firm had revenue of $665.50 million during the quarter, compared to analysts’ expectations of $600.68 million. Natera had a negative return on equity of 14.74% and a negative net margin of 9.05%.During the same quarter in the previous year, the business earned ($0.41) earnings per share. As a group, sell-side analysts anticipate that Natera, Inc. will post -1.59 EPS for the current year.

Natera Profile

Natera is a global diagnostics company that develops and commercializes cell-free DNA and other genetic testing technologies for clinical applications. The company focuses on three principal areas: reproductive health (including non-invasive prenatal testing and carrier screening), oncology (tumor-informed assays for minimal residual disease and recurrence monitoring), and organ transplantation (cell-free DNA tests to detect allograft injury). Natera combines laboratory testing, proprietary bioinformatics, and clinical reporting to deliver personalized genetic information to clinicians and patients.

Key product offerings include Panorama, a non-invasive prenatal test that screens for fetal chromosomal abnormalities and select single-gene conditions; Horizon carrier screening for inherited conditions; Signatera, a personalized, tumor-informed assay used for detecting minimal residual disease and monitoring treatment response in cancer patients; and Prospera, a donor-derived cell-free DNA test used to assess the risk of organ rejection.